Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Britannia Life SciencesXCNQ:BLAB Gross Margin % is 145.58% as of Mar. 2026, which is 195% above its 10-year median of 49.39. The stock has 5 warning signs investors should review. Among 737 Biotechnology companies, Britannia Life Sciences ranks worse than 82.9% on this metric.
Britannia Life Sciences (XCNQ:BLAB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Britannia Life Sciences had a gross margin of 145.58% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Britannia Life Sciences Gross Margin % Related Terms
Britannia Life Sciences Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:BLAB vs VRTX, REGN, MRNA: Gross Margin % Comparison
For the Biotechnology subindustry, Britannia Life Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Britannia Life Sciences Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Britannia Life Sciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Britannia Life Sciences (XCNQ:BLAB) has a Gross Margin % of 145.58% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Britannia Life Sciences and its competitors. This is 195% above median its historical median of 49.39. Over the past decade, Britannia Life Sciences' Gross Margin % has ranged from 7.32 to 82.25. According to the industry distribution chart, Britannia Life Sciences ranks #611 out of 737 companies in the Biotechnology industry, placing it in the top 82.9%.
Is Britannia Life Sciences' Gross Margin % too high?
Britannia Life Sciences' current Gross Margin % of 145.58% is 195% above median its 10-year median of 49.39. Over the past 10 years, this metric has ranged from a low of 7.32 to a high of 82.25. The Biotechnology industry median Gross Margin % is 61.00. Britannia Life Sciences' value of 145.58% is 138.7% above this industry median. Based on the distribution chart, Britannia Life Sciences ranks #611 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Britannia Life Sciences' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #611 out of 737 companies for Gross Margin %. This places Britannia Life Sciences in the lower half of its industry. The industry median Gross Margin % is 61.00. Britannia Life Sciences' value of 145.58% is 138.7% above this benchmark. Historically, Britannia Life Sciences' own Gross Margin % has ranged from 7.32 to 82.25 over the past decade. While the company's 10-year median is 49.39 vs. the industry median of 61.00, Britannia Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 61.00, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Britannia Life Sciences's current Gross Margin % of 145.58% is 138.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Britannia Life Sciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 61.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Britannia Life Sciences's current Gross Margin % is 145.58%, which is 195% above median its own 10-year median of 49.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (XCNQ:BLAB) has a current Gross Margin % of 145.58%. The current Gross Margin % is 145.58%, which is 195% above median its 10-year median of 49.39 and 138.7% above the Biotechnology industry median of 61.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Britannia Life Sciences (XCNQ:BLAB), the current Gross Margin % is 145.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:BLAB has been successfully added to your 
